According to an new article in the Journal of Biological Chemistry, the combination of metformin with a polo-like kinase 1 (Plk1) inhibitor known currently as BI2536 appears to be able to suppress the spread of prostate cancer that resists all other available treatments.
Obviously, this is very preliminary data, based on laboratory experiments in cell cultures and mice. The only currently available information comes from a media release issued by Purdue University — and we are always a little cautious about the claims made in media releases.
The effects reported in animal experiments will need to be replicated in men with metastatic, castration-resistant prostate cancer (mCRPC) before anyone should start to get too excited.
Filed under: Drugs in development | Tagged: BI2536, castration-resistant, mCRPC, metformin |
THE "NEW" PROSTATE CANCER INFOLINK 
Leave a Reply